Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
3.250
0.00 (0.00%)
At close: Aug 25, 2025, 4:00 PM
3.330
+0.080 (2.46%)
After-hours: Aug 25, 2025, 6:59 PM EDT

Company Description

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.

The company’s lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage.

It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN).

The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024.

Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Grace Therapeutics, Inc.
Grace Therapeutics logo
CountryUnited States
Founded2002
IndustryBiotechnology
SectorHealthcare
Employees6
CEOPrashant Kohli

Contact Details

Address:
103 Carnegie Center, Suite 300
Princeton, New Jersey 08540
United States
Phone609-322-1602
Websitegracetx.com

Stock Details

Ticker SymbolGRCE
ExchangeNASDAQ
Share ClassClass A Shares
Fiscal YearApril - March
Reporting CurrencyUSD
CIK Code0001444192
ISIN NumberUS00439U1043
SIC Code2834

Key Executives

NamePosition
Prashant KohliChief Executive Officer and Director
Amresh Kumar Ph.D.Vice President of Program Management
Carrie D'AndreaVice President of Clinical Operations
Robert J. DelAversano CPAVice President of Finance and Principal Financial and Accounting Officer
Dr. R. Loch MacDonald M.D., Ph.D.Member of Scientific Advisory Board and Chief Medical Officer

Latest SEC Filings

DateTypeTitle
Aug 14, 2025SCHEDULE 13G/AFiling
Aug 12, 20258-KCurrent Report
Aug 12, 202510-QQuarterly Report
Jul 28, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Jul 28, 2025DEF 14AOther definitive proxy statements
Jun 25, 20258-KCurrent Report
Jun 23, 20258-KCurrent Report
Jun 23, 202510-KAnnual Report
May 15, 2025SCHEDULE 13G/AFiling
May 15, 2025SCHEDULE 13GFiling